Blog Posts - Nasdaq:blrx



Rambus (RMBS) and Synaptics (SYNA) Increase Revenue Outlook, BioLineRx (BLRX) U.S. Patent Notice of Allowance for Celiac Disease Polymer

Rambus Inc. (RMBS) Keep a close eye on RMBS. The company has raised its revenue guidance, and now expects for the second quarter of 2014 revenue to range between $75 million and $77 million, up from the initial range of $69 million to $74 million. Fo...
by PennyOmega.com on Jun 11, 2014

BioLineRx (BLRX) Patent for a Short Peptide in Immunotherapy, Vaalco Energy (EGY) Strong Results

BioLineRx Ltd. (BLRX) BL-8040 is a clinical-stage drug candidate for the treatment of acute myeloid leukemia, as well as other hematological indications. It is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine recept...
by PennyOmega.com on Mar 14, 2014


Trending Topics

Close